文献速递胃肠动力与功能性疾病

胃轻瘫药物的疗效与安全性:系统综述与网络荟萃分析

Efficacy and Safety of Drugs for Gastroparesis: Systematic Review and Network Meta-analysis.
PubMed 文献 · Gastroenterology · 2022-12-26

该网络荟萃分析纳入截至2022年9月7日的29项随机对照试验共3772例胃轻瘫患者,评估多种药物的相对疗效与安全性。基于整体症状,氯波必利排名第一(RR 0.30,95%CI 0.16-0.57),多潘立酮次之(RR 0.68,95%CI 0.48-0.98),仅口服多巴胺拮抗剂(RR 0.58,95%CI 0.44-0.77)和速激肽-1拮抗剂(RR 0.69,95%CI 0.52-0.93)两类药物优于安慰剂,多数比较的证据置信度低至中等。

要点

  • 口服多巴胺拮抗剂和速激肽-1拮抗剂在整体症状上优于安慰剂,但多数比较证据置信度低至中等。
  • 氯波必利整体症状疗效排名第一(RR 0.30),多潘立酮次之(RR 0.68),其他药物未优于安慰剂。
  • 仅普芦卡必利与安慰剂相比更可能发生不良事件;胃轻瘫仍缺乏有效治疗。

核心结论

  • 口服多巴胺拮抗剂和速激肽-1拮抗剂对胃轻瘫的疗效优于安慰剂,但大多数比较的证据置信度低至中等。
  • 胃轻瘫仍存在未被满足的有效治疗需求。

研究设计与样本

  • 系统综述与随机对照试验的网络荟萃分析,检索文献至2022年9月7日。
  • 共纳入29项随机对照试验、3772例患者。
  • 疗效基于胃轻瘫整体症状及恶心、呕吐、腹痛、腹胀、饱胀等个体症状判定,安全性基于总不良事件及导致退出研究的不良事件。
  • 数据按意向性治疗分析提取,假设脱落为治疗失败,报告未改善的合并相对危险度(RR)及95%置信区间(CI),并按P分数对药物排名。

主要发现

  • 基于整体症状,氯波必利疗效排名第一(RR 0.30,95%CI 0.16-0.57,P分数=0.99),多潘立酮次之(RR 0.68,95%CI 0.48-0.98,P分数=0.76),其他药物均未优于安慰剂。
  • 仅两类药物有效:按排名顺序为口服多巴胺拮抗剂(RR 0.58,95%CI 0.44-0.77,P分数=0.96)和速激肽-1拮抗剂(RR 0.69,95%CI 0.52-0.93,P分数=0.83)。
  • 基于仅1项小型试验,口服甲氧氯普胺在恶心(RR 0.46,95%CI 0.21-1.00,P分数=0.95)、饱胀(RR 0.67,95%CI 0.35-1.28,P分数=0.86)和腹胀(RR 0.53,95%CI 0.30-0.93,P分数=0.97)方面排名第一。
  • 仅普芦卡必利与安慰剂相比更可能发生不良事件。

关键数值与推荐

  • 整体症状疗效排名:氯波必利RR 0.30(95%CI 0.16-0.57,P分数=0.99),多潘立酮RR 0.68(95%CI 0.48-0.98,P分数=0.76)。
  • 药物类别疗效:口服多巴胺拮抗剂RR 0.58(95%CI 0.44-0.77,P分数=0.96),速激肽-1拮抗剂RR 0.69(95%CI 0.52-0.93,P分数=0.83)。
  • 甲氧氯普胺个体症状排名(基于仅1项小型试验):恶心RR 0.46(95%CI 0.21-1.00,P分数=0.95),饱胀RR 0.67(95%CI 0.35-1.28,P分数=0.86),腹胀RR 0.53(95%CI 0.30-0.93,P分数=0.97)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 大多数比较的证据置信度为低至中等。
  • 甲氧氯普胺的个体症状排名仅基于1项小型试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Although there have been multiple drugs tested in gastroparesis, their relative efficacy and safety are unknown. We evaluated this in a network meta-analysis of randomized controlled trials (RCTs). METHODS: We searched the literature to September 7, 2022. We judged the efficacy of drugs based on global symptoms of gastroparesis; individual symptoms, including nausea, vomiting, abdominal pain, bloating, or fullness; and safety according to total adverse events and adverse events leading to withdrawal. We extracted data as intention-to-treat analyses, assuming dropouts to be treatment failures and reporting pooled relative risks (RRs) of not improving with 95% confidence intervals (CIs), ranking drugs according to P-score. RESULTS: We identified 29 RCTs (3772 patients). Based on global symptoms, clebopride ranked first for efficacy (RR, 0.30; 95% CI, 0.16-0.57; P-score = .99) followed by domperidone (RR, 0.68; 95% CI, 0.48-0.98; P-score = .76). No other drug was superior to placebo. Only 2 drug classes were efficacious: in rank order, oral dopamine antagonists (RR, 0.58; 95% CI, 0.44-0.77; P-score = .96) and tachykinin-1 antagonists (RR, 0.69; 95% CI, 0.52-0.93; P-score = .83). For individual symptoms, oral metoclopramide ranked first for nausea (RR 0.46; 95% CI, 0.21-1.00; P-score = .95), fullness (RR 0.67; 95% CI, 0.35-1.28; P-score = .86), and bloating (RR 0.53; 95% CI, 0.30-0.93; P-score = .97), based on only 1 small trial. Only prucalopride was more likely to be associated with adverse events than placebo. CONCLUSIONS: In a network meta-analysis, oral dopamine antagonists and tachykinin-1 antagonists were more efficacious than placebo for gastroparesis, but confidence in the evidence was low to moderate for most comparisons. There is an unmet need for efficacious therapies for gastroparesis.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Ingrosso MR, Camilleri M, Tack J, et al. Efficacy and Safety of Drugs for Gastroparesis: Systematic Review and Network Meta-analysis. Gastroenterology. 2022. PMID: 36581089. doi:10.1053/j.gastro.2022.12.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。